Core Viewpoint - The company is focusing on international market opportunities for its pharmaceuticals, specifically through a collaboration with Sinovac Biotech for the commercialization of Anglatavir tablets in Macau, which aims to enhance its brand presence overseas and support its international expansion efforts [1] Group 1 - The company has established a commercial partnership with Sinovac Biotech for Anglatavir tablets in Macau [1] - This collaboration is intended to create a brand radiating effect in international markets [1] - The company plans to explore further international market opportunities and accelerate its globalization efforts [1] Group 2 - The company is closely monitoring disease dynamics and is committed to effective drug production and sales [1]

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth as of October 23, 2025, highlighting the top 10 and bottom 10 funds [2][4][6] - The top-performing funds include 泰信现代服务业混合, 泰信发展主题混合, and various 招商中证煤炭等权指数 funds, with 泰信现代服务业混合 showing a net value of 1.7280 [2][6] - The bottom-performing funds include 中航优选领航混合发起C and 中航优选领航混合发起A, with 中航优选领航混合发起C showing a net value of 1.7109 [4][6] Group 2 - The overall market performance indicates a slight increase in the Shanghai Composite Index, with a trading volume of 1.66 trillion and a stock gain-loss ratio of 2994:2302 [6] - Leading sectors include oil and chemical fibers, both showing gains of over 2%, while sectors like communication equipment and construction materials faced declines [6] - The article notes that 泰信现代服务业混合 has experienced rapid net value growth, indicating strong performance in the current market environment [6]

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced a decline recently, despite a significant increase in its price year-to-date, indicating potential volatility in the market [1]. Financial Performance - As of June 30, Kexing Pharmaceutical reported a revenue of 700 million yuan, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 80.34 million yuan, showing a substantial increase of 576.45% [2]. - Cumulatively, Kexing Pharmaceutical has distributed dividends amounting to 51.54 million yuan since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2]. - The top ten circulating shareholders include notable funds such as E Fund Healthcare Industry Mixed A and others, with significant increases in holdings for some [3].

Core Insights - The successful shipment of the first batch of Bevacizumab biosimilar to Colombia marks a significant milestone for the company in deepening its presence in the Latin American market [1] Group 1: Overseas Commercialization Strategy - The company has been actively advancing the overseas registration of its collaborative products, receiving industry acclaim for its "multi-country registration" commercial efficiency [2] - The innovative "global selection + global coverage" outbound platform model has led to partnerships with several well-known pharmaceutical companies, securing over twenty key products for overseas commercialization across diverse therapeutic areas [2] - Colombia, as the fourth largest pharmaceutical market in Latin America, has seen a notable increase in the export of Chinese pharmaceutical products, with a 10.4% year-on-year growth in the first quarter of 2025 [2] Group 2: Regulatory and Market Entry - The Colombian pharmaceutical market is a key focus for the company, with the local regulatory body INVIMA's standards closely aligned with international authorities like the FDA and EMA, indicating a high level of market entry rigor [2] - The INVIMA certification is expected to facilitate the introduction of Bevacizumab in other Latin American markets, enhancing the company's overall market penetration strategy [2] Group 3: Collaborative Efforts and Future Plans - The successful commercialization of Bevacizumab overseas is attributed to the deep collaboration between the company and its partner, which ensures stringent production compliance and high product quality [3] - The company plans to continue advancing the registration of Bevacizumab in Latin America and other key markets, while also enhancing its local operational capabilities for other products [3] - The ongoing efforts aim to expand the company's international footprint and provide hope for more patients through access to essential medications [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Meeting Overview - The second extraordinary general meeting of shareholders was held on October 17, 2025, at the Innovation Technology Building in Shenzhen [5] - The meeting was convened by the board of directors and chaired by Chairman Deng Xueqin, utilizing a combination of on-site and online voting methods [2][3] Attendance - All 8 current directors attended the meeting, along with the board secretary Wang Xiaoqin and other senior management personnel [3] Resolutions Passed - The following key resolutions were approved during the meeting: - Proposal for the company to issue H-shares and list on the Hong Kong Stock Exchange [4] - Various aspects of the H-share issuance, including types and par value, issuance timing, method, scale, pricing, and target investors, were all approved [6][7] - The proposal to convert the company into an overseas fundraising joint-stock company was approved [7] - The fundraising usage plan for the H-share issuance was approved [7] - Authorization for the board of directors and its authorized personnel to handle matters related to the H-share issuance was approved [7] - Profit distribution plan prior to the H-share issuance was approved [7] - Amendments to the company's articles of association and related rules post-H-share issuance were approved [8] Legal Verification - The meeting was witnessed by Beijing Jiayuan Law Firm, confirming that the convening, procedures, and voting were in compliance with relevant laws and regulations [10]

证券代码：688136 证券简称：科兴制药 公告编号：2025-088 科兴生物制药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 17 日 （二） 股东会召开的地点：深圳市南山区高新中一道与科技中一路交汇处创益 科技大厦 B 栋 19 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 80 | | --- | --- | | 普通股股东人数 | 80 | | 2、出席会议的股东所持有的表决权数量 | 112,192,882 | | 普通股股东所持有表决权数量 | 112,192,882 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 56.6324 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.6324 ...

北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025 年第二次临时股东会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 SRE Jites 务 所 A YUAN LAW OFFICES · 深圳 SHENZHEN·香港 HONG KONG · 广州 GUANGZHOU· 西安 XI'AN 北京 BEIJING · 上海 SHANGHAI 致:科兴生物制药股份有限公司 北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025年第二次临时股东会的 法律意见书 嘉源(2025)-04-744 北京市嘉源律师事务所(以下简称"本所")接受科兴生物制药股份有限公 司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称"《公 司法》")、《上市公司股东会规则》(以下简称"《股东会规则》")等现行 有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及 《科兴生物制药股份有限公司章程》(以下简称"《公司章程》")的有关规定, 指派本所律师对公司2025年第二次临时股东会(以下简称"本次股东会")进行 见证,并依法出具本法律意见书。 一、本次股东会的召集与 ...

Core Viewpoint - The strategic cooperation agreement between the company and Chengdu Yuandong Biopharmaceutical Co., Ltd. aims to enhance the commercialization of Apalutamide tablets in multiple international markets, focusing on prostate cancer treatment [1] Group 1 - The company has signed a strategic cooperation agreement with Chengdu Yuandong Biopharmaceutical Co., Ltd. in 2023 [1] - The agreement includes exclusive overseas commercialization authorization for Apalutamide tablets in over ten countries, including Indonesia, Egypt, Saudi Arabia, and Colombia [1] - This collaboration aims to deepen the partnership and promote the drug's entry into potential markets in Southeast Asia, the Middle East, and Latin America [1]

恒指跌0.43%，恒生科技指数跌1.36%。中兴通讯涨7.14%，老铺黄金涨6.28%，康方生物涨5.57%，中煤 能源涨5.42%，泡泡玛特涨5.05%；东岳集团跌5.98%，巨子生物跌12.31%；药捷安康-B涨42.12%，佰泽 医疗涨19.43%。 ...